909 results on '"Pirenne, France"'
Search Results
152. Autologous blood extracellular vesicles and specific CD4+ T-cell co-activation.
153. [Blood transfusion and blood products: indications, complications. Haemovigilance]
154. Remdesivir failure with SARS-CoV-2 RNA-dependent RNA-polymerase mutation in a B-cell immunodeficient patient with protracted Covid-19
155. A New Delayed Hemolysis Transfusion Diagnosis Score Based on Intra Vascular Hemolysis Parameters
156. [What to remember from blood transfusion?]
157. RHCE*01 48G>C, 366del allele with silenced RHCE*ce expression
158. Whole‐blood CCR7 expression and chemoattraction in red blood cell alloimmunization
159. RHCE*cE734C allele encodes an altered c antigen and a suppressed E antigen not detected with standard reagents
160. Insights intoanti‐Dformation in carriers ofRhDvariants through studies of3Dintraprotein interactions
161. Heme control to major B (cell): are you listening?
162. Convalescent Plasma Improves Overall Survival in Patients with B-Cell Lymphoid Malignancies and COVID-19: A Longitudinal Cohort and Propensity Score Analysis
163. HLA molecule expression on the surface of cells and microparticles in platelet concentrates
164. Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
165. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response
166. Dominant immune response to HLA‐B57/B58 molecules after platelet transfusion
167. Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019
168. Automated RBC Exchange has a greater effect on whole blood viscosity than manual whole blood exchange in adult patients with sickle cell disease
169. New molecular basis associated with CD36 ‐negative phenotype in the sub‐Saharan African population
170. Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease
171. Blood microparticles are a component of immune modulation in red blood cell transfusion
172. Partial C antigen in sickle cell disease patients: clinical relevance and prevention of alloimmunization
173. Delayed hemolytic transfusion reaction in sickle cell disease patients: evidence of an emerging syndrome with suicidal red blood cell death
174. Predisposing factors for anti-D immune response in D − patients with chronic liver disease transfused with D + platelet concentrates
175. Weak D phenotypes and transfusion safety: where do we stand in daily practice?
176. Duffy and Kidd blood group antigens: minor histocompatibility antigens involved in renal allograft rejection?
177. Relative immunogenicity of Fya and K antigens in a Caucasian population, based on HLA class II restriction analysis
178. ceRA: an RH allele variant producing a new rare blood
179. Tolerance of Liver Transplant Patients to Strenuous Physical Activity in High-Altitude
180. RhD variants in Caucasians: consequences for checking clinically relevant alleles
181. The molecular basis of the Rhesus antigen Ew
182. Molecular background of D(C)(e) haplotypes within the white population
183. Two new alleles of the RHCE gene in Black individuals: the RHce allele ceMO and the RHcE allele cEMI
184. Emerging RNA-Dependent RNA Polymerase Mutation in a Remdesivir-Treated B-cell Immunodeficient Patient With Protracted Coronavirus Disease 2019.
185. ABO blood group and COVID‐19: a review on behalf of the ISBT COVID‐19 Working Group.
186. Complement activation in sickle cell disease: Dependence on cell density, hemolysis and modulation by hydroxyurea therapy
187. Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal
188. In memoriam Docteur Rachid DJOUDI
189. A proposal for a rational transfusion strategy in patients of European and North African descent with weak D type 4.0 and 4.1 phenotypes
190. Human Apoptotic Cells, Generated by Extracorporeal Photopheresis, Modulate Allogeneic Immune Response
191. Causes of Death in 198 Sickle Cell Adult Patients: Old and New Trends
192. Treatment of Delayed Hemolytic Transfusion Reactions in Sickle Cell Disease Patients By an Anti-C5 Antibody
193. Interest of a New Method for Free Plasma Heme Related Species Dosages in Sickle Cell Disease and Beta Thalassemia
194. Development of a Personalized 3D Carotid Model for Cerebral Vasculopathy Monitoring in Sickle Cell Disease
195. Rituximab for Preventing Delayed Hemolytic Transfusion Reaction (DHTR) in Sickle CELL Adult Patients: Outcome of Transfusion and SIDE Effects in 58 CASES
196. Fetal Hemoglobin Measurement per Red Blood Cell Provides Biological and Clinical Protective Thresholds
197. Still celebrate the World Blood Donor Day and shed light on blood donation needs and blood demand
198. Allo-immunisation et efficacité des techniques d’immuno-hématologie chez les patients auto-immunisés
199. Daratumumab et interférences au laboratoire d’IH : 2015–2018, retour d’expérience de l’EFS Ile-de-France
200. Étude de l’allo immunisation anti-érythrocytaire sur la base des déclarations e-FIT
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.